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Polyomavirus, discovered by Ludwik Gross as a con- 
taminant in a murine leukemia virus preparation in the 
early 1950s, was termed polyomavirus by Sarah Stewart 
and Bernice Eddy because of its ability to elicit multiple 
different ypes of tumors in mice. By 1960, culture condi- 
tions for growing polyomavirus in vitro had been devel- 
oped, and its ability to "transform" cells in culture had 
been established. Because of the ease of propagation 
and the small size of its double-stranded DNA genome 
(<5 kb), polyomavirus quickly became one of the favor- 
ite model systems for studying the process of carcino- 
genesis. The hope was that an understanding of how 
this simple tumor virus transforms cells would shed light 
on the mechanisms underlying the human disease. The 
isolation of temperature-sensitive polyomavirus mu- 
tants defective in transformation at the restrictive tem- 
perature and the identification of viral transcripts in 
transformed cells suggested that a viral gene product 
might be responsible for the transformed state. In addi- 
tion, rodents infected with polyomavirus had been found 
to develop antibodies against polyomavirus-infected 
cell-specific antigens, which became known as T (tumor) 
antigens. Although formal proof that the T antigens are 
encoded by the polyomavirus genome had to wait sev- 
eral more years, at the time it seemed plausible that 
these proteins were indeed virally coded and that one 
or more of them had oncogenic properties. When the 
work that ultimately led to our paper began in 1977, there 
was intense interest in the identity of the polyomavirus T 
antigen proteins and the molecular basis for their ability 
to transform cells. 
From the early days, the Saik Institute had been a 
mecca for the study of polyomavirus because Renato 
Dulbecco, a founding faculty member of the Institute in 
1964, had been one of the pioneers in studying poly- 
omavirus and had trained a cadre of young investigators 
who went on to study polyomavirus in their own 
groups--these included Mike Fried who moved to ICRF 
in London, Tom Benjamin who moved to Harvard Medi- 
cal School, and Walter Eckhart who stayed at the Salk 
Institute to set up his own group studying polyomavirus. 
During 1977 and early 1978, we, together with Mary 
Anne Hutchinson, had been busy characterizing the 
polyomavirus T antigens by peptide mapping of immu- 
noprecipitated metabolically labeled proteins, com- 
bined with analysis of virus deletion mutants and in vitro 
translation of virally derived mRNAs and cRNAs. For 
polyomavirus, three different sized T antigens had been 
identified by Yoshi Ito and Renato Dulbecco, who had 
moved to ICRF in 1972 (Ito et al., 1977a, 1977b). These 
became known rather unimaginatively as large, middle, 
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and small T antigens. We (Hutchinson et al., 1978; Hunter 
et al., 1978), at the same time as John Smart and Yoshi 
Ito (Smart and Ito, 1978), found that the three T antigens 
had a common N-terminal region but also each had 
unique peptides, suggesting an unusual structural rela- 
tionship. With the completion of the nucleotide se- 
quence of the polyomavirus genome by our collabora- 
tors, Prescott Deininger and Ted Friedmann at UCSD, 
we were able to prove that all three T antigens are indeed 
virally encoded and also to define the coding regions 
for the three T antigens (Hunter et al. 1979). We found 
that the C terminus of the middle T antigen is translated 
from the same sequence as part of the large T antigen, 
but in a different reading frame, and that the very C 
terminus of small T antigen is derived from the third 
reading frame. At about this time, the first evidence for 
splicing of adenovirus and SV40 mRNAs was emerging, 
and in due course it was found that the mRNAs for 
the large, middle, and small T antigens are derived by 
different alternative splicing events from a single precur- 
sor RNA transcribed from the so-called early region of 
the viral genome--a prime example of how genetic infor- 
mation is compacted into a small genome. 
Genetic analyses indicated that the large and middle 
T antigens had distinct functions in cell transformation 
and that the large T antigen was required for viral DNA 
replication, but the biochemical functions of the proteins 
were not known. Moreover, in contrast o the v-s rc  onco- 
gene of the RNA tumor virus, Rous sarcoma virus (RSV), 
the transforming region of the polyomavirus genome 
was not recognizably of cellular origin, nor were any of 
the three polyomavirus T antigens related in sequence 
to proteins of known function. Nevertheless, the middle 
T antigen was of particular interest because another 
small DNA tumor virus, simian virus 40, although similar 
in size and in overall genetic organization, does not 
encode a middle T antigen, and evidence was emerging 
that middle T antigen itself is required for transformation. 
The next question was how does middle T transform 
cells. 
In thinking about how polyomavirus T antigens might 
transform cells, we were prompted to look for protein 
kinase activity associated with the T antigens because 
of the discovery, made independently by the Erikson and 
Bishop/Varmus groups, that p60 vs~ (v-Src), the protein 
encoded by the RSV v-s rc  gene, had an associated 
protein kinase activity (Collett and Erikson, 1978; Levin- 
son et al., 1978). This kinase activity could be detected 
as result of phosphorylation of the antibody heavy chain 
or v-Src itself, when immunoprecipitates containing 
v-Src were incubated in kinase buffer with ~-32P-labeled 
ATP, a protocol that became known as the immune 
complex kinase assay. This result electrified the cancer 
research community because protein phosphorylation 
was a well-established principle for reversible regulation 
of protein activity, and it immediately suggested that 
v-Src transformed cells through phosphorylation of a set 
of target proteins, thus altering their activity. Moreover, 
Hartmut Beug and Thomas Graf had just shown that 
cytoplasts made from chick cells transformed with a ts 
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Figure 1. Historic Moments in the Discovery of Phosphotyrosine 
mutant of RSV undergo reversible morphological changes 
in response to temperature shift (Beug et al., 1978), 
suggesting that this aspect of the transformed pheno- 
type is itself reversible and is therefore mediated by a 
reversible process such as protein phosphorylation. We 
were intrigued by the notion that there might be a univer- 
sal principle of transformation and that other tumor vi- 
ruses, including DNA tumor viruses like polyomavirus, 
use phosphorylation as a mechanism of transformation. 
We quickly set out to test whether polyomavirus T anti- 
gens might have an associated protein kinase activity. 
Using immune complex kinase assays, we found that 
immunoprecipitates of polyomavirus T antigens from 
infected cells indeed did contain a protein kinase activity 
that in this case resulted in the phosphorylation of the 
middle T antigen (Eckhart et al., 1979). This protein ki- 
nase activity was absent from precipitates containing 
only large and small T antigens or that had nontrans- 
forming mutant middle T antigen, thus correlating with 
transforming function and implying that the activity was 
somehow dependent on middle T antigen itself. 
At the XLIV Cold Spring Harbor Symposium, held May 
31-June 5, 1979, we learned that two other groups, Alan 
Smith, Mike Fried, and Beverly Griffin at the ICRF in 
London and Brian Schaffhausen and Tom Benjamin at 
Harvard Medical School, had also detected kinase activ- 
ity associated with the polyomavirus middle T antigen. 
We all agreed to submit our papers descd6ing these 
findings as soon as possible to Cell, with the hope that 
they would be published back to back. In the rush to 
get our paper submitted, we did not carry out the con- 
ventional analysis to determine whether middle T anti- 
gen becomes phosphorylated on serine or threonine, 
which at the time were the only known phosphoryiated 
amino acids in proteins. But we assumed this was simply 
a formality that could be done while the paper was being 
revised (indeed one of the reviewers requested these 
data!). Our paper was submitted to Cell on June 13,1979. 
On June 12, Tony Hunter set up the first experiment 
to determine the identity of the phosphorylated amino 
acid in polyomavirus middle T antigen. He isolated 32p_ 
labeled middle T protein, phosphorylated in an immuno- 
precipitate, and separated the amino acids released by 
acid hydrolysis on a cellulose thin layer plate by electro- 
phoresis, using a homemade water-cooled flat bed ap- 
paratus and a lab stock of pH 1.9 buffer that had already 
been used several times before. Following autoradiogra- 
phy, he found a radioactive spot running between the 
stained phosphoserine (P.Ser) and phosphothreonine 
(P.Thr) markers, but to his surprise it did not comigrate 
with either of them (as he recorded rather laconically in 
his experimental notes "spot does not coincide with 
P.Ser and P.Thr internal markers") (Figure 1). After re- 
peating the experiment to make sure that the result was 
not an artifact, he speculated that the phosphorylated 
amino acid might be tyrosine since tyrosine was the 
only other hydroxyamino acid in proteins, and, like serine 
and threonine, it would be expected to generate an acid- 
stable phosphate ester if phosphorylated. 
Tyrosine phosphorylation of proteins, however, had 
never been reported, and no phosphotyrosine (P.Tyr) 
marker was available. Without realizing that a chemical 
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synthesis for P.Tyr had been devised in 1941 (Plimmer, 
1941), Tony made a small quantity of P.Tyr by the decid- 
edly suboptimal method of mixing POCI3 with tyrosine 
in aqueous solution. Initial experiments howed that the 
~2P-labeled compound comigrated with chemically syn- 
thesized P.Tyr upon one-dimensional separation at pH 
1.9. To be certain of the identification, Tony devised a 
two-dimensional separation system using pH 1.9 elec- 
trophoresis followed by chromatography in the second 
dimension and used this to confirm that acid hydroly- 
sates of 32P-labeled polyomavirus middle T antigen con- 
tained a phosphoamino acid that comigrated with the 
synthetic P.Tyr marker in both dimensions. 
Although by this time we were reasonably convinced 
that middle T antigen was being phosphorylated on tyro- 
sine in vitro, because tyrosine phosphorylation was un- 
precedented, we were unsure whether this was a genu- 
ine end-state posttranslational modification or whether 
it might represent an unusually stable phosphoenzyme 
intermediate. We were aware that the VPg protein of 
poliovirus is linked to the virion RNA through a phos- 
phate ester bond between a tyrosine in VPg and the 5' 
uridylic acid residue of the RNA (Ambros and Baltimore, 
1978; Rothberg et al.,. 1978), but we could not find any 
reports of a protein kinase activity that phosphorylated 
tyrosine, and this was confirmed by discussions with 
Ed Krebs, Gordon Gill, and several other protein phos- 
phorylation mavens. 
Because we had some remaining concern that P.Tyr 
might possibly be generated from 3=P-labeled middle T 
antigen by an acid-catalyzed reaction during acid hydro- 
lysis, rather than as a result of phosphorylation by a 
tyrosine-specific protein kinase, Tony tested whether 
P.Tyr could be released from 32p-labeled middle T anti- 
gen by complete proteolysis as well as by acid hydroly- 
sis. During this time, he had been collaborating with our 
Tumor Virology Laboratory colleagues, Karen Beemon 
and Bart Seffon, to characterize the v-Src protein kinase 
activity, and this enabled him to use 32P-labeled immuno- 
globulin heavy chain phosphorylated by v-Src in an im- 
munoprecipitate from RSV-transformed cells as one of 
the acid hydrolysis controls. This was expected to yield 
P.Thr, based on the report from Marc Collett and Ray 
Erikson that v-Src phosphorylates threonine in the heavy 
chain (Collett and Erikson, 1978). Much to his surprise, 
Tony found that the only phosphorylated amino acid 
released was P.Tyr, which he confirmed by two-dimen- 
sional separation (P.Tyr and P.Thr migrate together us- 
ing the conventional technique of paper electrophoresis 
at pH 1.9, which accounts for the original conclusion). 
Deciding to repeat the v-Src experiments to generate 
publication data, Tony made up fresh pH 1.9 electropho- 
resis buffer and found to his chagrin that synthetic P.Tyr 
and P.Thr now comigrated. He speculated that the "old" 
buffer must have changed in some way to allow resolu- 
tion of P.Tyr and P.Thr. It turned out that the pH of the 
buffer had dropped from 1.9 to 1.7 with repeated use. 
in retrospect, his use of the "old" buffer was a crucial 
part of the whole discovery. For a time, we had to use 
deliberately "aged" buffer in our experiments to sepa- 
rate P.Tyr and P.Thr. Based on a suggestion by our 
colleague Jack Rose, who was familiar with how the 
VPg tyrosine phosphate diester linkage had been char- 
acterized (Ambros and Baltimore, 1978; Rothberg et al., 
1978), Tony and Bart Sefton subsequently developed 
an improved two-dimensional separation for the three 
phosphoamino acids, using electrophoresis at pH 1.9 
followed by electrophoresis at pH 3.5, a method that is 
still in use today. 
Tony and Bart Sefton then set out to determine 
whether tyrosine phosphorylation actually occurs in 
vivo. They found that v-Src, isolated from 32P-labeled 
RSV-transformed chick embryo fibroblasts, contained 
both P.Tyr and P.Thr and that a cellular protein that 
coprecipitated with v-Src also contained P.Tyr. Further- 
more, they observed an approximately 10-fold increase 
in the level of P.Tyr in total proteins in RSV-transformed 
chick cells compared to untransformed cells, strongly 
implying that v-Src acts as a protein-tyrosine kinase in 
vivo. In cells transformed by a ts mutant of RSV, they 
found that P.Tyr levels were elevated at the permissive 
temperature, when cells were transformed, and were 
low in the untransformed cells at the restrictive tempera- 
ture (Sefton et al., 1980). Moreover, the level of P.Tyr 
fell within 30 min of shifting cells from the permissive 
to the restrictive temperature, implying the existence of 
protein-tyrosine phosphatases that could rapidly de- 
phosphorylate proteins phosphorylated by v-Src. Ironi- 
cally, polyomavirus-transformed cells did not contain 
elevated levels of P.Tyr in proteins (Sefton et al., 1980). 
Subsequently, Sara Courtneidge and Alan Smith showed 
that the tyrosine kinase activity in middle T antigen im- 
munoprecipitates i not intrinsic to middle T, but rather 
due to association with c-Src (Courtneidge and Smith, 
1983). Middle T antigen itself and signaling proteins 
downstream of the middle T antigen/c-Src omplex can 
be shown to contain P.Tyr in polyomavirus transformed 
cells, but the total activity of activated c-Src in poly- 
omavirus-transformed cells is much lower than that of 
v-Src in RSV-transformed cells, explaining the failure to 
find increases in P.Tyr in whole-cell protein analysis. 
The fact that the tyrosine kinase activity of temperature- 
sensitive mutant v-Src was temperature sensitive in vitro 
strongly implied that this activity was an intrinsic prop- 
erty of v-Src, but it was not until the protein sequence 
of the catalytic subunit of the cAMP-dependent protein 
kinase was reported revealing a close relationship to 
the C-terminal half of the predicted v-Src sequence that 
this was formally established (Barker and Dayhoff, 1982). 
By the time we were ready to submit our revised manu- 
script on the phosphorylation of polyomavirus T anti- 
gens in the fall of 1979, we were convinced that tyrosine 
phosphorylation was real and important. We revised the 
manuscript o include the identification of tyrosine as 
the phosphorylated amino acid, changing the title to 
emphasize that observation, and the paper was resub- 
mitted on September 21. The paper was published in 
Cell in December, 1979, together with those of the 
Schaffhausen/Benjamin (Schaffhausen, and Benjamin, 
1979) and Smith/Griffin/Fried (Smith et al., 1979) groups, 
which described similar findings, but without identifica- 
tion of phosphoryiated tyrosine in middle T antigen. 
The initial response to our discovery of protein-tyro- 
sine kinase activity in polyomavirus T antigen immuno- 
precipitates was muted. It was not until a few months 
later, in the spring of 1980, when observations of tyrosine 
phosphorylaUon by retroviral transforming proteins were 
published, that the significance of the discovery began 
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to be widely appreciated. At the same time that Tony and 
Bart reported their findings on v-Src and c-Src tyrosine 
phosphorylation i  vitro and in vivo (Hunter and Sefton, 
1980), Owen Witte, Asim Dasgupta, and David Baltimore 
at MIT reported that v-Abl was phosphorylated on tyro- 
sine in vitro ((Witte et al., 1980). Although they concluded 
that the P.Tyr in v-Abl was likely to reflect the formation 
of a phosphoenzyme intermediate, their finding of P.Tyr 
reinforced the observations made on Src. Subsequent 
work by Marc Collett, Tony Purchio, and Ray Erikson 
showed that purified v-Src can phosphorylate a number 
of nonphysiological substrates on tyrosine, reinforcing 
the notion that v-Src is a true prootein-tyrosine kinase 
(Collett et al., 1980). 
Even though tyrosine phosphorylation was an unprec- 
edented process, there was almost no opposition to the 
idea that this is a genuine physiological process, and it 
was quickly adopted by the research community. In 
1978, Stanley Cohen at Vanderbilt had reported that the 
EGF receptor was an EGF-stimulated protein-threonine 
kinase (Carpenter et al., 1978). Once he learned that 
P.Thr and P.Tyr are not resolved by electrophoresis at 
pH 1.9, he and Hiroshi Ushiro re-examined the amino 
acid specificity of the EGF receptor kinase and found 
that it too phosphorylated tyrosine (Ushiro and Cohen, 
1980). This finding provided a link between the EGF 
receptor and retroviral oncoproteins like v-Src and v-Abl 
and suggested that neoplastic cell transformation by 
viral protein-tyrosine kinases might involve activation of 
signaling pathways stimulated by growth factor re- 
ceptors. 
It seems clear now that cell transformation by v-Src 
results from the phosphorylation of cellular proteins on 
tyrosine. Although numerous substrates have been 
identified, including proteins that are also targets of 
growth factor receptor protein-tyrosine kinases, exactly 
which substrates are crucial for the transforming activity 
of v-Src remains an enigma. In contrast, cell transforma- 
tion by the polyomavirus middle T antigen appears to 
result from the activation of growth signaling pathways 
by a middle T/c-Src complex. The c-Src protein kinase 
activity phosphorylates tyrosines in middle T antigen, 
which, in turn, act as binding sites for adaptor molecules 
or downstream signaling effectors, including Shc, which 
activates the Ras/ERK MAP kinase pathway, and phos- 
phatidylinositol-3' kinase. 
Our discovery of tyrosine phosphorylation during our 
studies of polyomavirus T antigens was made possible 
by several fortunate circumstances. One was the dedi- 
cation and technical expertise of Mary Anne Hutchinson, 
who refined the immunoprecipitation, immune complex 
kinase assays, and electrophoretic separations that fa- 
cilitated all our experiments. Another was the interactive 
environment created by our colleagues in the Tumor 
Virology Laboratory at the Salk Institute, who helped us 
through many stimulating discussions and collabora- 
tions. Additionally--and not least--was the accidental 
discovery that "aged" pH 1.9 electrophoresis buffer al- 
lowed the separation of P.Tyr and P.Thr. In retrospect, 
it was a lot of fun. 
Initially, we did not foresee that tyrosine phosphoryla- 
tion would be such an important signaling mechanism 
or the underlying cause for many types of human cancer. 
When we told our story to Renato Dulbecco in Septem- 
ber 1979, he immediately suggested that tyrosine phos- 
phorylation might be a common basis for cell transfor- 
mation. His instinct was rapidly vindicated. By the end 
of 1980, we knew of four tyrosine kinases, three retroviral 
transforming proteins, v-Src, v-Abl, and v-Fes, in addi- 
tion to the EGF receptor, and by 1982, the insulin recep- 
tor and the PDGF receptor had been added to the list. 
Twenty years later, as a result of the completion of the 
human genome sequence, we now know that the human 
genome encodes 90 distinct yrosine kinases. The early 
hints in 1979 that aberrant tyrosine phosphorylation 
might play a role in human disease have been borne 
out, and more than half of the 90 human tyrosine kinases 
have been implicated in the genesis of at least one type 
of cancer (Blume-Jensen and Hunter, 2001). Gratifyingly, 
Gleevec TM, the first drug that acts as a tyrosine kinase 
inhibitor ('I'KI) was approved by the FDA in 2001 for 
cancer therapy, and it is proving a very effective treat- 
ment for early stage chronic myelogenous leukemia, a 
disease driven by Bcr-Abl, an activated form of the Abl 
tyrosine kinase, as well as for gastrointestinal stromal 
tumors, where an activated mutant form of the c-Kit 
stem cell factor receptor or the PDGF receptor is respon- 
sible. A second TKI, Iressa TM, an EGF receptor inhibitor, 
has also recently been approved for cancer therapy. 
These TKIs are the harbingers of what will surely became 
a major new class of cancer drugs. 
Figure 2. Still Riding the Wave (Artist: Jamie Simon) 
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